Vaxcyte (PCVX) is trading higher as investors react to momentum in its late-stage VAX-31 program, following a recent update that the company completed enrollment in two Phase 3 trials (OPUS-1 and OPUS-2). The enrollment milestone de-risks execution risk (recruiting) and refocuses attention on upcoming immunogenicity and safety readouts that could shape the company’s path toward a future filing.

For clinical-stage vaccine developers, enrollment completion is often treated as a meaningful operational inflection point because it locks in a clearer timeline to data and reduces uncertainty around trial pace. Vaxcyte has guided to OPUS-1 topline data in Q4 2026, while OPUS-2 data are anticipated in the first half of 2027; OPUS-3 remains ongoing with results expected in the first half of 2027. Investors are positioning around these catalysts because they represent the company’s most consequential near-term value drivers for VAX-31 in adults.

VAX-31 is Vaxcyte’s next-generation pneumococcal conjugate vaccine candidate designed to expand serotype coverage beyond currently marketed adult options, and the Phase 3 program is structured across multiple adult settings, including concomitant administration with a seasonal influenza vaccine (OPUS-2) and previously vaccinated adults (OPUS-3). The next key checkpoints are continued progress in OPUS-3, confirmation that follow-up stays on track, and any updates that refine the probability of regulatory success and commercial positioning as the market’s standard of care evolves.